Cleveland BioLabs (CBLI) is a nano-cap company working to advance their radiation countermeasures in the military and civilian spaces in addition to other potential indications for their lead drug - entolimod. This company has been striving towards this goal for the past decade and has led investors on a wild goose chase with ever-lengthening trials and long promised opportunities. During this time, the stock has flatlined and now sits squarely in the de-listing range below $1. This is far from the company's first foray into this price range, as they have performed large reverse splits